You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

What’s New in the Drug Formulary

All new and recently updated drug and regimen monographs, patient information sheets, as well as safety and advice documents are available here.

Drug

Published Date: 27 Feb 2026

Revision Summary:
Patient Info Sheet EN: Updated/Revised drug information sheet
Patient Info Sheet FR: Updated/revised information sheet (Fiche d’information mise à jour/révisée)
Updated
Feb 2026
Regimen
Published Date: 27 Feb 2026
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Updated
Feb 2026
Drug

Published Date: 26 Feb 2026

Revision Summary:
Drug Monograph: Updated Adverse Effects, Dosing, Administration, and Special Precautions sections
Updated
Feb 2026
Drug

Published Date: 26 Feb 2026

Revision Summary:
Drug Monograph: Updated Adverse Effects, Dosing, Administration, and Special Precautions sections
Patient Info Sheet EN: Updated/revised information sheet
Patient Info Sheet FR: Updated/revised information sheet (Fiche d'information mise à jour/revisée)
Updated
Feb 2026
Regimen
Published Date: 26 Feb 2026
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
Revision Summary:

Regimen Monograph: Updated Adverse Effects and Administration sections

Updated
Feb 2026
Regimen
Published Date: 25 Feb 2026
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Revision Summary:

Regimen Monograph: new ST-QBP regimen

New
Feb 2026
Regimen
Published Date: 25 Feb 2026
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Revision Summary:

Regimen Monograph: Updated Rationale/Uses, Supplementary Public Funding, Drug Regimen, and Cycle Frequency sections

Updated
Feb 2026
Regimen
Published Date: 25 Feb 2026
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Revision Summary:

Regimen Monograph: Updated Rationale/Uses, Supplementary Public Funding, Drug Regimen, and Cycle Frequency sections

Updated
Feb 2026
Regimen
Published Date: 25 Feb 2026
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Revision Summary:

Regimen Monograph: Updated Rationale/Uses, Supplementary Public Funding, Drug Regimen, and Cycle Frequency sections

Updated
Feb 2026
Regimen
Published Date: 25 Feb 2026
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Neoadjuvant, Curative
Revision Summary:

Regimen Monograph: Updated Rationale/Uses, Supplementary Public Funding, Drug Regimen, and Cycle Frequency sections

Updated
Feb 2026
Regimen
Published Date: 25 Feb 2026
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
Revision Summary:

Regimen Monograph: Updated Rationale/Uses, Supplementary Public Funding, Drug Regimen, and Cycle Frequency sections

Updated
Feb 2026
Regimen
Published Date: 25 Feb 2026
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Revision Summary:

Regimen Monograph: Updated Dose Modifications, Adverse Effects, and Drug Administration/Special Precautions sections

Updated
Feb 2026

Pages